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Mark Aaron Vanden Avond 
Systemic administration of the NTS1 receptor agonist PD149163 has exhibited anxiolytic 
effects in male rats. The present study sought to further evaluate the potential anxiolytic 
effects of PD149163 by assessing this compound in both male and female C57BL/J6 
mice using the fear-potentiated startle (FPS) paradigm.  Startle chambers were equipped 
with a shock-grid floor, fluorescent light, and an acoustic startle speaker.  Conditioning 
took place between the light and floor shock, and test sessions measured startle to a 90 
dB noise burst while the light was on (FPS) or off.  Startle magnitude did not differ 
between the male and female mice.  PD149163 produced a significant difference between 
male and female mice startle response and a significant reduction in FPS in females. The 
NTS2 receptor agonist β-Lactotensin produced a sex difference at an intermediate dose.  
The anxiolytic and partial 5-HT1A agonist buspirone did not produce a significant 
difference in FPS.  The reduction in FPS by PD149163 coincides with previous studies 
conducted in male rats.  The reduction in FPS found in female mice suggests that more 
research is needed to examine the neurotensin system and sex differences.  Overall, these 
findings support targeting the neurotensin system for the development of novel strategies 
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 The Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-
5) defines anxiety as the exaggerated anticipation of a future threat and is associated with 
muscle tension and preparation for future danger.  While anxiety and fear are related, the 
DSM-5 clarifies that fear is an emotional response to a real or perceived imminent threat 
with autonomic arousal necessary for fight or flight, whereas anxiety is an exaggerated 
response to a future threat (American Psychiatric Association, 2013).  A substantial 
amount of research shows that anxiety disorders can persist throughout one’s lifetime if 
left untreated (Beesdo, Knappe, and Pine, 2009; Beesdo, Pine, Leib, and Wittchen, 2010; 
Burstein, Beesdo-Baum, He, and Merikangas, 2014; Kessler, Andrade, Bijl, Demler, and 
Stein, 2002; Kessler et al., 2005; Lieb, Becker, and Altamura, 2005; Mohr & Schneider 
2013; Wittchen, 2002).   
 Separation anxiety disorder, selective mutism, specific phobia, social anxiety 
disorder, panic disorder, agoraphobia and generalized anxiety are defined as anxiety 
disorders in the DSM-5.  While each anxiety disorder has a specific definition, there are 
common symptoms among each disorder.  These common symptoms are: a reaction that 
is more intense, to a stimulus, event, or perceived stimulus, actively avoiding the 
stimulus, event, or perceived stimulus, and occurs for six months or longer (American 




 Anxiety disorders not only cause a burden on the individual, but also on society.  
About forty-two percent of adults have or have had anxiety disorders and anxiety 
disorders are the second highest prevalence for mental disorders (Kessler, Petukhove, 
Sampson, Zaslavsky, and Wittchen, 2012; Lieb et al., 2005).  Lieb et al. (2005) estimates 
that generalized anxiety disorder costs around $250 per month for an individual, and 
Eaton, Martins, Nestadt, Binevenu, Clarke, and Alexandre (2008) estimates around $11 
billion per year for specific phobia.  Anxiety can cause a decrease in work production and 
quality of life, an increase in seeking medical practices, and impairment and disability 
(Leib et al., 2005; Wittchen, 2002).   
 Anxiety disorders are more prevalent in women in their lifetime.  In their 
lifetimes, about thirty-three percent of women will be diagnosed with an anxiety disorder 
compared to twenty-two percent of men (McLean, Asnaani, Litz, and Hofmann, 2011).  
Girls have been shown to have rates of anxiety disorders twice that of boys at as early as 
the age of six (Lewinsohn, Gotlib, Lewisohn, Seeley, and Allen, 1998).  Women with 
anxiety disorders are more likely than men to seek medical help and will miss more days 
of work (McLean et al., 2011).     
Neurocircuitry of Anxiety  
 The neurocircuity mediating anxiety involves complex interactions between a 
number of structures, including the amygdala, septum, ventral tegmental area, 
periaqueductal gray (PAG), hypothalamic-pituitary-adrenal axis, and the orbitofrontal 




The amygdala, in particular, has long been considered a “fear center” in the brain.  
In humans, higher amygdala volume is correlated with more anxiety (Qin, Young, Daun, 
Chen, Supekar, and Menon, 2014).  The amygdala mediates fear and anxiety in animal 
behavioral models.  The basolateral amygdala responds to cues that predict danger 
(Amano, Duvarci, Popa, and Pare, 2011).  The basolateral amygdala projects to the 
central nucleus of the amygdala (Tye et al., 2011).  Hitchcock & Davis (1986) found that 
in male rats bilateral lesions of the central nucleus of the amygdala blocked the 
potentiation of the startle reflex using a fear-potentiated startle paradigm in their 
experiment.  An external cue, which was previously combined with an aversive stimulus, 
was used to produce an exaggerated startle response in the fear-potentiated startle 
paradigm.  In male rats, an electrolytic lesion of the pathway between the central nucleus 
and the caudal lateral hypothalamus also blocked the fear-potentiated startle response, 
providing further evidence that the amygdala is necessary.  Moreover, the lateral 
hypothalamus may play a role as well (Hitchcock & Davis, 1991).  The central nucleus of 
the amygdala also projects to the nucleus reticularis pontis caudalis (Rosen, Hitchcock, 
Sananes, Miserenino and Davis, 1991).  The nucleus reticularis pontis caudalis is 
important for the production of the fear-potentiated startle response.  Davis, Gendelman, 
Tischler and Gendelman (1982) lesioned this area in male rats which abolished the 
acoustic startle, and lesions more rostral, caudal or dorsal did not abolish the startle, 
providing evidence that this area is important for the fear-potentiated startle response.   
 The septum is another important region in the production of anxiety-related 
behaviors. The lateral septum has been shown to connects the amygdala to the 




2015).  The elevated-plus maze is another behavioral test used to measure levels of 
anxiety.  Anxiety is assessed in an elevated-plus maze by recording the number of entries 
and total time spent in open arms (i.e., those without walls) compared to closed arms of a 
maze positioned at a certain height (e.g., 50 cm) above the floor.  An increase in entries 
and time spent in the open arm of the elevated-plus maze shows a decrease in anxiety-
related behavior.  A group of male rats with the lateral septum lesioned showed an 
increase in the percentage of open arm entries and percentage of time spent in the open 
arm.  Similar results were found in male rats with medial septal lesions (Menard & Treit, 
1995). 
 The ventral tegmental area (VTA) in the midbrain is also important for stress and 
anxiety-related behaviors.  Quinpirole, a dopamine D2/3 agonist, administered into the 
VTA has blocked fear-potentiated startle.  Another study showed that lesions of the 
medial ventral tegmentum also blocked fear-potentiated startle.  These findings provide 
evidence that dopamine neurons in the VTA are important for anxiety (Munro & 
Kokkinidis, 1997; Borowski & Kokkinidis, 1996).  Mukherjee et al. (2010) showed that 
when circadian locomotor output cycles kaput (Clock) genes are deleted in mice, Clock
-/-
 
mice had an increased firing rate of dopaminergic neurons in the VTA.  The Clock
-/-
 mice 
showed lower anxiety behavior indicatd by increased time spent in the open arm of the 
elevated-plus maze and time spent in the middle of an open field compared to wild-type 
mice. These results suggests that there is less anxiety in the Clock
-/-
 mice.  Reduced 
anxiety was no longer evident after Clock protein levels in the VTA of Clock
-/-
 mice 
returned to levels comparable to wild-type mice via viral-mediated gene transfer (Roybal 




 Lesions of the PAG before or after fear-conditioning training (light + shock 
conditioning sessions) provided evidence that the PAG is implicated in the expression of 
fear-potentiated startle response.  Lesioning the PAG of male rats before or after training 
inhibited potentiated startle caused by a light cue (Fendt, Koch, and Schnitzler, 1996).  
Pharmacologically, intra-PAG infusion of the serotonin (5-HT)2B/2C receptor agonist, 
meta-chlorophenylpiperazine (mCPP), decreased anxiety-like behavior in male mice 
using the elevated-plus maze.  Pretreatment of the 5-HT2A/2C receptor antagonist, 
ketanserin, blocked the anxiolytic effects of mCPP which provides evidence that the 5-
HT2C receptor is important for anxiety in the PAG (Nunes-de-Souza, Nunes-de-Souza, 
Rodgers, and Canto-de-Souza, 2008).   
 The hypothalamic-pituitary-adrenal axis mediates sympathetic nervous system 
activity.  The corticotrophin-releasing hormone neurons in the hypothalamus activate the 
anterior pituitary gland.  The pituitary gland, in turn, releases adrenocorticotropic 
hormone, which causes the adrenal gland to release cortisol.  The corticotrophin-releasing 
hormone neurons in the hypothalamus are activated in preparation for an urgent situation.  
Flandreau, Ressler, Owens, and Nemeroff (2011) have shown that a hyperactive 
hypothalamic-pituitary-adrenal axis can cause behavior associated with anxiety.  This 
study examined Wistar rats using a battery of anxiety tests, including the open field test, 
elevated plus maze, defensive withdrawal, and forced swim test and showed an increase 
in adrenocorticotropic hormone concentrations.   
 The orbitofrontal cortex is important in processing reward and punishment, which 
assigns value to stimuli.  The medial orbitofrontal cortex examines the reward value of 




(for review, see Kringlebach and Rolls, (2004). Thus, the amygdala and orbitofrontal 
cortex act together to assign fear memories to conditioned stimuli. 
Common Pharmacological Treatments for Anxiety Disorders 
Historically, barbiturates were some of the first drugs used to treat anxiety 
(Lopez-Munoz, Ucha-Udabe and Alamo, 2005).  Barbiturates bind to an allosteric site on 
the GABAA receptor, causing a conformational change that increases chloride 
conductance when the receptor is activated by an agonist (Sankar, 2012).  Dixon, Rosahl 
and Stephens (2008) used GABRA2 knockout mice, which are missing the genes that 
encode the GABAA α2-subunit, and showed that pentobarbital hydrochloride did not have 
any anxiolytic effects.  This provides evidence that the GABAA α2-subunit is important 
for the allosteric site that barbiturates bind to, and therefore is important for the anxiolytic 
effects (i.e., anti-anxiety effects) of barbiturates.  However, barbiturates have negative 
effects.  Barbiturates have a high abuse potential (Lopez-Munoz et al., 2005; McClane & 
Martin, 1976)  and a marginal therapeutic range during chronic use.  Thus, chronic 
barbiturates use can easily lead to overdose (Lopez-Munoz et al., 2005).  Moreover, 
barbiturates have been linked to many suicides (Gunnell & Eddleston, 2003).   
 Benzodiazepines were discovered in the 1960’s.  Benzodiazepines, like 
barbiturates, affect the GABA receptor (Sigel & Buhr, 1997).  Like barbiturates, 
benzodiazepines will bind an allosteric site on the GABAA receptor and increase the rate 
of which Cl
-
 channels open to increase chloride conductance (Sankar, 2012).   The 
benzodiazepine chlordiazepoxide increased the amount of entries to the open arm of the 
elevated-plus maze in mice when compared to saline, providing evidence that 




(Belzung, Le Guisquet, and Griebel, 2000).  The benzodiazepine diazepam decreased 
fear-potentiated startle in male mice (Risbrough, Brodkin, and Geyer, 2003) and 
increased time spent in the open arms of an elevated plus maze (Cole & Rodgers, 1995).  
Benzodiazepines replaced barbiturates for the treatment of anxiety disorders because the 
risk of abuse potential is relatively lower compared to barbiturates (Smith & Rudolph, 
2012).  Benzodiazepines can cause sedation and cognitive deficits and long-term use can 
lead to dependency and withdrawal symptoms (Durham, 2007; Glombok, Moodley, and 
Lader, 1988).  Also, benzodiazepines can cause psychomotor retardation, which can 
produce slower reaction times that can impair driving skills and can cause anterograde 
amnesia (Longo and Johnson, 2000).   
 Antidepressants were used in the 1960’s for the treatment of anxiety disorders.  
The first antidepressants used for anxiety were monoamine oxidase inhibitors (MAOI), 
but tricyclic (TCA) and serotonin reuptake inhibitor (SSRI) antidepressant drugs are 
more widely used for long-term treatment of anxiety disorders (Sargant and Dally, 1962; 
Durham, 2007).  MAOIs increase monoamines in the synapse by inhibiting the enzyme 
that breaks down the monoamines.  TCAs increase synaptic serotonin and norepinephrine 
by blocking the reuptake mechanism, along with binding to other receptors, such as the 
histamine H1 receptor (Owens, Morgan, Plott, and Nemeroff, 1997).  SSRIs are effective 
by inhibiting the serotonin reuptake transport, which increases serotonin in the synapse.  
MAOIs and TCAs are usually prescribed when SSRIs are not treating anxiety disorders 
effectively, and are second- or third-line treatments due to their potential side effects. 
(Sayed, Horn, and Murrough, 2014).  For example, MAOIs interact with foods containing 




Walker, and Tailor, 1996).  Teixeira, Zangrossi, and Graeff (2000) showed that acute 
administration of the antidepressant imipramine increased escape latencies, while chronic 
imipramine reduced escape latencies in male rats.  Similar acute effects were found using 
sertraline, an SSRI.  Sertraline increased startle in a fear-potentiated startle procedure, 
which could be an indication of increased anxiety.  Fluoxetine treatment did not show a 
significant difference (Steiner, Lecourt, and Jenck, 2012).  While efficacy for both 
tricyclic antidepressants and SSRIs are similar, SSRIs are prescribed more frequently due 
to their safety and tolerability (Zohar, 2000).  Antidepressant drugs take a few weeks for 
any therapeutic effects to occur.  Along with delayed activation, antidepressant drugs are 
only effective for about sixty percent of patients (Prus, 2014).  This could be because 
male rats given acute administration of fluoxetine, sertraline, and the 5-HT agonist mCPP 
displayed decreased social interactions and increased self-grooming (Bagdy, Graf, 
Anheuer, Modos, and Kantor, 2001).  Decreasing social interactions between rats and 
increasing self-grooming is an indication of high levels of anxiety.   
Neurotensin 
 Neurotensin (NT) is a 13-amino-acid neuropeptide found in the central nervous 
system and peripheral nervous system.  As many other neuropeptides, NT acts as a 
neuromodulator in the nervous system and is closely associated with dopamine systems 
(St-Gelais, Jomphe, and Trudeau, 2006).  In the VTA and substantia nigra NTS1 receptors 
are expressed on about eighty to ninety-five percent of dopamine neurons (Binder, 
Kinkead, Owens and Nemeroff, 2001; Dana et al., 1989).  Dopamine neurons either 
increase or decrease firing depending on the abundance of NT; high concentrations of NT 




firing (Jiang, Pessia, and North, 1994; Farkas, Chien, Shigehiro and Nakajima, 1997; Wu 
& Wang, 1995).  NT utilizes three receptor iosforms, NTS1, NTS2 and NTS3/sortilin 
receptors, and has the highest affinity for NTS1 receptors followed by NTS2 receptors.  
The neurotensin receptors are g-protein coupled receptors (Luca et al, 2003), which 
interact with dopamine receptors to decrease D2 receptor agonist binding affinity (Binder, 
Kinkead, Owens, and Nemeroff, 2001).   
The NTS1 receptor can be found throughout many brain areas, which corresponds 
to evidnece that NT plays a role in anxiety, schizophrenia, drug abuse, neurodegenerative 
diseases, pain, and many other disorders (St-Gelais et al., 2006; Prus, Hillhouse, and 
LaCrosse, 2014).   Boudin, Pelaprat, Rostene and Beaudet (1996) were the first to image 
the NTS1 receptor in the whole mammalian brain using immunohistochemistry to identify 
the receptor (see table 1). Of particular relevance to anxiety, NTS1 receptors were found 
in the posterior cortical nucleus of the amygdala on perikarya, dendrites, and axon 
terminals.  The hippocampus also contains NTS1 receptors on cell bodies, dendrites, and 
axon terminals.  In the diencephalon, the thalamus and anterior dorsal nucleus found 
perikarya labeled for NTS1 receptors. The hypothalamus contained NTS1 receptors on 
axon terminals throughout the medial and lateral subdivisions and in the median 
eminence.   
Table 1: Neurotensin receptor locations 
Brain area Dendrites Perikarya/ 
Cell Body 
Axon Terminals 
Frontal Cortex: Layer II-III  + +  
Frontal Cortex: Layer IV +    
Frontal Cortex: Layer V  +   




Parietal Cortex: Layer IV +    
Parietal Cortex: Layer V  +   
Anterior Cingulate Cortex: Layer IV    + 
Endopiriform Cortex: Layer IV    + 
Insular Cortex: Layer IV    + 
Perirhinal Cortex: LayerI-III and VI    + 
Entorhinal Cortex   +   
Retrosplenial Cortex: Layers I    + 
Retrosplenial Cortex: Layers II-III  +  + 
Caudate Putamen  +  + 
Nucleus Accumbens: Core and Shell   +  
Anterior Commissure   +  
Islands of Calleja + +   
Septum  + +  
Broca  +   
Preoptic Nucleus +    
Bed Nucleus of the Stria Terminalis  + +  
Amygdala + +  + 
Thalamus  +   
Optic Tract + +   
Hypothalamus    + 
Suprachiasmatic Nucleus   +  
Lateral Mammillary Nucleus   +  
Subthalamus + +   
Epithalamus  +   
Habenula  +   
Substantia Nigra + +   
Pars Compacta + +   
Ventral Tegmental Area + +   
Interfascicular Nucleus + +   
Nucleus Raphe Linearis Caudalis + +   
Periaquductal Gray + +   
Dorsal Raphe + +   
Latrodorsal Tegmental Nuclei + +   
Tegmentum   +  
Locus Coeruleus   +  
Tegmental Nucleus  +   
Medulla  +   
Pontine Nuclei  +   
Reticular Formation  +   
Inferior Olivary Nucleus + +   
Paragigantocellular Nucleus + +   
Vagus + +   





 While NT is found throughout the brain and has different behavioral implications, 
little has been studied with NT and differences between males and females.  NT 
expression is similar in male and female rats until puberty when sex hormones begin to 
change NT levels (Bello et al., 2004; Ciofi, 2000).  Ovariectomized female rats given 
estradiol treatments expressed more NT when compared to ovariectomized female rats 
that were not given estradiol treatments (Ciofi, 2000).  However, Dufourny & 
Warembourg (1999) did not find ovariectomized female guinea pigs to have a significant 
change in NT immunoreactivity when subjects were given estradiol treatments.  The 
differences in NT expression post estradiol treatment could be due to species differences.  
Mice could have a more similar NT system to primates than rats.  In areas of the brain, 
such as the subthalamic nucleus, mice and primates express NT mRNA while rats do not.  
While rats did not have a NT containing neurons in some areas, rats also had neurotensin 
containing neurons in areas where mice and humans did not.  A neurotensin-dopamine 
pathway projects to the prefrontal cortex, the nucleus accumbens and amygdala in rats, 
but is not found in mice or humans (Smits, Terwisscha, van Scheltinga, van der Linden, 
Burbach, and Smidt, 2004).  NT concentrations were found to be different between males 
and females in a number of brain regions, including: the prefrontal cortex, nucleus 
accumbens, hippocampus, and substantia nigra.  Due to the estrous cycle of female rats, 
NT concentrations also vary in the VTA, nucleus accumbens, and anterior 
caudate/putamen depending on where the female is during the cycle (Kinkead et al., 




Neurotensin Pharmacological Agents in Anxiety Models 
Few studies have examined the potential effects of NT on anxiety.  Fitzpatrick et 
al. (2012) have found that NTS1 receptor knockout male mice traveled less and spent less 
time in the center using an open field test compared to wild-type controls.  These effects 
have been associated with higher levels of anxiety.  However, a significant difference 
was not found between the knockout mice and controls using an elevated plus maze.  
These findings show that the ‘anxious’ phenotype of the knockout mice might be 
dependent on the environment and context.  Further research needs to examine the effects 
that environment and NT has on anxiety.  Ollmann et al. (2015) demonstrated an increase 
in time spent in the open arms of an elevated plus maze after bilateral microinjections of 
NT into the ventral pallidum in male rats showing an anxiolytic effect.  PD149163, a NT1 
receptor agonist, has been shown to decrease conditioned footshock-induced ultrasonic 
vocalizations, which is an indication of anxiolytic effects (Prus et al., 2014).  Shilling & 
Feifel (2008) found that PD149163 reduced fear-potentiated startle in male rats, but also 
decreased the startle magnitude.  This suggests that PD149163 may produce unintended 
effects, such as decreased locomotor activity, which could explain the decreased fear-
potentiated startle effect.   An even smaller amount of research has been conducted on the 
pharmacology of the NTS2 receptor and the effects on anxiety.  Male wild-type mice 
were given β-lactotensin, a NTS2 receptor agonist, and time spent in the open arms of the 
elevated plus maze increased (Hou et al., 2011).  Further research needs to examine the 




Fear-Potentiated Startle Paradigm 
 The fear-potentiated startle paradigm was first introduced in 1951 partly on the 
anecdotal observation that patients with an anxiety disorder had an exaggerated startle 
response to a sudden loud noise (Brown, Kalish, and Farber, 1951).  Initially, rats were 
conditioned using a light-buzzer conditioned stimulus (CS) presented for five seconds 
with a unconditioned stimulus (UCS) shock initiating for the last two seconds of the CS.  
It was believed that the CS-UCS pairing would lead to an anticipatory fear reaction.  To 
test this, a startle stimulus was presented in place of the shock and the magnitudes of the 
jumps were recorded using a stabilimeter-like apparatus.  The magnitudes of the jumps 
were compared to a group that did not have the CS-UCS presented simultaneously, but 
were presented the same amount of light-buzzer and shocks as the experimental group.   
The experimental group produced a higher startle magnitude to a sudden sound when 
compared to the control group (Brown et al., 1951).    
 Further studies have used pharmacological agents to study the effects on fear-
potentiated startle.  Extensive research has evaluated treatments that alter 
neurotransmitters and their effects on potentiated startle (see table 2) (Cassella & Davis, 
1985; Chi, 1965; Davis, 1979; Davis, 1986; Davis, Cassella, and Kehne, 1988; Davis, 
Falls, Campeau, and Kim, 1993; Davis, Redmond, and Baraban, 1979; Hijzen & Slangen, 







Table 2: Effect of drugs on FPS 




























α1 adrenoceptor Antagonist No Effect 
Yohimbine α2  adrenoceptor Antagonist Increase 
Startle 














GABA Antagonist Increased 
Startle 
Flumazenil GABAA Antagonist No Effect 























Antagonist No effect 
Raclopride Dopamine D2/3 Antagonist Decreased 
Startle 
SCH23390 Dopamine D1 Antagonist Decreased 
Startle 



























Naloxone Opioid Mu Antagonist No Effect 
Buspirone Serotonin 5-HT 1A Partial Agonist Blocked 
Potentiatio
n 
Cinanserin Serotonin 5-HT 
2A/2C  
Antagonist No Effect 
Cyproheptadine Histamine H1 Antagonist No Effect 
Gepirone  Serotonin 5-HT1A Partial Agonist Blocked 
Potentiatio
n 
Tropisetron Serotonin 5-HT3 Antagonist Decreased 
Startle 




Antagonist No Effect 
m-CPP Serotonin 5-HT2C Agonist No Effect 









Ondansetron Serotonin 5-HT3 Antagonist Decreased 
Startle 
p-Chloroamphetamine Serotonin releaser  No Effect 





Drugs that affect the adrenoceptors were shown to have different effects on 
potentiated startle.  Agonists, such as clonidine or propranolol, blocked potentiated 
startle, while antagonists, such as piperoxan and yohimbine, increased potentiated startle.  
Imipramine (acute and chronic) and WB4101, an agonist and antagonist respectively, had 
no effects on potentiated startle (Davis et al., 1979; Davis et al., 1993; Cassella & Davis, 
1985).   
Drugs that facilitate GABA neurotransmission were found to inhibit potentiated 
startle.  Positive modulators of the GABA receptor, such as amobarbital, diazepam, 
flurazepam and midazolam, blocked potentiated startle, while DMCM and flumazenil, 
GABAA receptor antagonists, increased and had no effect on potentiated startle, 
respectively (Chi, 1965; Davis, 1979; Davis et al., 1979; Davis et al., 1993; Hijzen & 
Slangen, 1989).   
Drugs that affect dopamine receptors have shown a differential effect.  Dopamine 
releasers, such as cocaine and d-amphetamine, increased potentiated startle, while 
dopamine receptor antagonists, such as raclopride and SCH23390, decreased potentiated 
startle.  Dopamine receptor antagonists in combination with serotonin receptor agonists, 
SCH23390 + 8-OH-DPAT, SCH23390 + ipsapirone, have blocked potentiated startle 
(Davis et al., 1993; Borowski & Kikkindis, 1998).   
Many drugs have been used to study the effects of the 5-HT receptor and their 





ipsapirone, either block or decrease potentiated startle.  Cinanserin, cyproheptadine and 
ketanserin, all 5-HT receptor antagonists, had no effect potentiated startle, while other 5-
HT receptor antagonists, tropisetron, methysergide, ondansetron, and fenclonine, 
decreased potentiated startle (Mansbach & Geyer, 1988; Davis et al., 1988; Davis et al., 
1993).  The differential effects of the 5-HT receptor antagonists may be due to the 
different receptor subtypes affected.   
 Lesion studies have identified structures important for FPS.  Tischler & Davis 
(1983) have found that lesions of the dorsal nucleus of the lateral geniculate nucleus, 
deep layers of the superior colliculus, visual cortex, and posteroventral region of the 
nucleus of the lateral lemniscus attenuated or eliminated potentiated startle, while lesions 
to the pretectal nuclei, superficial layers of the superior colliculus, thalamic reticular 
nucleus, nucleus reticularis pontis caudalis or dorsal nucleus of the lateral lemniscus did 
not attenuate potentiated startle.  Lesions of the amygdala blocked a potentiated startle 
while lesions to the cerebellum or red nucleus did not (Hitchcock & Davis, 1986).  
Lesions to the caudal ventral amygdalofugal pathway and substantia nigra blocked 
potentiated startle, while lesions to the rostral ventral amygdalofugal pathway and 6-
OHDA lesions of substantia nigra did not block potentiated startle (Davis, 1986).  With 
the main “fear center” in the brain being the amygdala, Campeau & Davis (1995) showed 
that lesions to the central nucleus and basolateral complex of the amygdala blocked 
potentiated startle.  When the hippocampus was lesioned freezing was attenuated, but 
fear-potentiated startle was not affected (McNish, Gewirtz, and Davis, 1997). Thus, 




Most FPS research has involved rodents as test subjects; however, primates and 
humans have also been studied and can exhibit a FPS response (Grillon & Davis, 1997).  
Diazepam and morphine decrease potentiated startle in a dose-dependent manner in 
rhesus monkeys, an effect previously found in rodents (Winslow, Nobel, and Davis, 
2007).  Norrholm et al. (2006) were the first to show within-session fear extinction and 
reinstatement using startles in humans.  This is important, because humans and non-
human animals show similar physiological effects; there is a greater translational value in 
studying when studying non-human animals.  The next logical step would be to examine 
how anti-anxiety drugs affect FPS in humans, and Patrick, Berthot, and Moore (1996) 
showed that diazepam, a clinically used benzodiazepine, blocked potentiated startle, an 
effect previously found in rodents and non-human primates (Davis et al., 1993).  The FPS 
paradigm was even used to test new types of drugs for clinical use.  Grillon, Cordova 
Levine Charles, and Morgan (2003) examined the effects of LY35470, a glutamate 
receptor agonist, on FPS in humans, and found a reduction in potentiated startle along 
with subjective data suggesting a decrease of overall anxiety levels.  Hormones have also 
been tested.  Female participants were given injections of testosterone which reduced 
potentiated startle.  Hermans, Putman, Baas, Koppeschar, and van Honk (2006) were able 
to study sex differences, and further supported the notions that testosterone mediates sex 
differences in fears.   
Given that clinically used anti-anxiety drugs, such as diazepiam and buspirone, 
and lesion studies have shown to block or decrease potentiated startle, this gives the FPS 
paradigm evidence for support to study anxiety.  Further support in using the FPS 





 As mentioned previously, anxiety disorders are prevalent in society and are the 
second most diagnosed mental disorders.  Current treatments, benzodiazepines and 
antidepressants, have considerable side effects.  Benzodiazepines can be addictive and 
can cause sedation and cognitive deficits.  Antidepressants are effective in only about 
sixty percent of people with an anxiety disorder and have many different side effects.  
NTS1 receptor agonists have been shown to have a potential anxiolytic effect.  Research 
also suggests a role for the NTS2 receptor having anxiolytic effects (Hou et al., 2011).  
The majority of behavioral studies using neurotensin drugs have been studied in male 
rodents, which limits the translational value of research to humans.  Using NTS1 and 
NTS2 receptor agonists in male and female mice is the next logical step for advancing 
exploration for treating anxiety.   
Therefore, the present study was conducted to examine the NTS1 receptor agonist 
PD149163, and the NTS2 agonist β-Lactotensin, on fear-potentiated startle in male and 
female mice.  We hypothesize that the NTS1 receptor agonist, PD149163, and the NTS2 
receptor agoninst, β-Lactotensin, will significantly decrease FPS, buspirone, previously 
shown to decrease FPS, will act as our positive control, and male and female mice will 









Forty-five male and 45 female wild-type C57/BL6 mice (Mus musculus) (Charles 
River, Portage, MI) were used as subjects.  Subjects were about two months old upon 
arrival and weighted between 18 and 25 grams before drug tests.  Animals were housed 
three to a cage with food and water provided ad libitum.  Animals were maintained in a 
climate-controlled room with a 14/10-h light/dark cycle (lights on at 7.30).  Behavioral 
training and testing occurred two to three weeks after arrival and between 8.00 and 16.00.  
Animal care and experiments were conducted in accordance with The Guide to Care and 
Use of Laboratory Animals and was approved by the Institutional Animal Care and Use 
Committee (protocol 254) at Northern Michigan University, Marquette, MI.   
Test Compounds 
PD149163 and β-lactotensin were generously provided by RTI International 
(Piedmont, NC) and administered at doses of 0.1, 0.3 and 1.0 mg/kg (Carey, 2014; Hou et 
al., 2011).  Buspirone was purchased from Sigma-Aldrich (St. Louis, MO) and 
administered at doses of 1.25, 2.5, and 5 mg/kg (Risbrough et al., 2003).  The salt forms 
of the drugs were used.  All test compounds were dissolved in saline, and was 





Two startle chambers were commercially built (Med Associates Inc., St. Albans, 
VT) and consisted of a Plexiglas cage with steel rod floor bars.  A scrambled current was 
delivered to the steel rod floors to serve as footshocks.  The cages rested on a platform 
that transduced animal movements into digital recordings via the Startle Reflex software 
(Med Associates Inc.).  Florescent lights were placed next to the cages to serve as a 
conditioned stimulus (see below).  Speakers were placed alongside the cages and 
produced a startle stimulus (0.20 sec, 90 dB, white noise burst) and a red light on the top.  
The cages and other instruments were placed in sound-attenuated cabinets equipped with 
fans for ventilation and masking noise.  A computer controlled and recorded all data from 
the startle chambers using Startle Reflex (Med Associates Inc.) in the experimental room.   
The open-field consisted of two rectangular, open-top boxes (built from laminated 
melamine).  Each box measured 30 x 30 x 27cm.  A camera was mounted 71cm from the 
center of each box and recorded and analyzed locomotor activity using Noldus 
EthoVision video software (Leesburg, VA).  A lightbulb was placed 80cm from the 





Training procedures were similar to those described by Risbrough et al. (2003).  
The purpose of these conditioning trials was to pair the light (conditioned stimulus) with 
the elicitation of shock (unconditioned stimulus).  The expected result was that the 




response) when the light is on.  A conditioning session consisted of ten trials.  A session 
began with a 5-min acclimation period, consisting of a red chamber light and ventilation 
fan turning on, but no experimental events.  Following the acclimation period, ten trials 
(separated by 120-180 sec) began and each trail consisted of a stimulus light activating 
for 10 s and co-terminating with a 0.30 mA shock (0.25 sec duration) delivered to the 
floor of the nonrestrictive cage (Figure 1a).  
Testing 
A series of drugs were tested in the mice, with N = 15 per group.  One drug was 
tested in each group, but mice within each group were tested with three doses of the test 
drug, in addition to a saline test given before testing drug doses and a final saline test 
given after testing drug doses.  The three doses of each drug were tested in a counter-
balanced, ascending order.  For example, the test order for mouse FPS5 was saline, 
PD149163 0.3 mg/kg, PD149163 1.0 mg/kg, PD149163 0.1 mg/kg, and saline.  Test 
sessions were separated by six to seven days.  After a dose has been tested, one training 
session was conducted the day prior to the next test session in order to maintain 
conditioning with the light-shock pairing.   
A testing session consisted of 24 trials.  A session began the same as a training 
session.  Following the acclimation period, ten startle stimuli (0.20 sec, 90 dB, white 
noise burst) separated by 20 s occurred in the dark to habituate the subject to the startle 
burst before the light cue turned on.  Then, 24 trials (separated by 120-180 sec) consisted 
of either a stimulus light activated for 10 sec preceding the activation of a startle stimulus 




of the trials consisted of the light-startle stimulus pairing and half consisted of the startle 
stimulus only (i.e., with no preceding stimulus light (Figure 1b).   
                                                                                                                  Stimulus light on 
a Training trials                                                                                        Stimulus light off 
 
0          9.80  10           130-190 sec 
b Testing trials 
 
0          9.80  10     130-190 sec        130-190 sec 
 
Figure 1: Schematic description of stimulus presentation during training and test trials.  
(a) Training trials.  Ten training trials consisted of a ten sec light cue co-terminating with 
a 0.30 mA scrambled footshock during the last 0.25 sec.  A dark period followed the light 
period which varied 120 to 180 sec.  (b) Testing trials.  Twenty-four trials consisted of a 
stimulus light turning on for ten seconds and co-terminating with a 0.20 sec, 90 dB, white 
noise burst startle stimulus, followed by a dark period of 120-190 sec.  Twelve of the 
trials consisted of the stimulus light on, while twelve trials consisted of the stimulus light 
off.   
Open-Field Test 
 Immediately following fear-potentiated startle tests, mice were placed in the 
center of the open-field for five minutes.  During this open-field session, total path-length 




entered and left the center of the open field was measured.  Following each trail, the 
open-field was cleaned using isopropyl alcohol. 
Data Analysis 
 The first ten startle stimuli of the test session were used to habituate the animals 
to the startle stimulus and were not used in the data analysis.  The dependent variables 
measured for the FPS test sessions were FPS (+/- standard error of the mean [SEM]) and 
mean startle magnitude (+/- SEM).  The FPS was calculated as follows: 
(
𝑠𝑡𝑎𝑟𝑡𝑙𝑒 𝑚𝑎𝑔𝑛𝑖𝑡𝑢𝑑𝑒 𝑓𝑜𝑟 𝑙𝑖𝑔ℎ𝑡 𝑛𝑜𝑖𝑠𝑒 𝑡𝑟𝑖𝑎𝑙𝑠 − 𝑠𝑡𝑎𝑟𝑡𝑙𝑒 𝑚𝑎𝑔𝑛𝑖𝑡𝑢𝑑𝑒 𝑓𝑜𝑟 𝑛𝑜𝑖𝑠𝑒 𝑜𝑛𝑙𝑦 𝑡𝑟𝑖𝑎𝑙𝑠
𝑠𝑡𝑎𝑟𝑡𝑙𝑒 𝑚𝑎𝑔𝑛𝑖𝑡𝑢𝑑𝑒 𝑓𝑜𝑟 𝑛𝑜𝑖𝑠𝑒 𝑜𝑛𝑙𝑦 𝑡𝑟𝑖𝑎𝑙𝑠
) ∗ 100 
 
 (Shilling & Feifel, 2008; Walker & Davis, 2002; Winslow, Nobel and Davis, 
2007).  This calculation provides the percentage of startle occurring from the difference 
between the white noise burst when the stimulus light was on and off above the intensity 
of startle occurring from the white noise burst when the stimulus light was off.  The 
dependent variable for the open field tests were total path length (cm) total time spent in 
the center of the box (sec), and total number of times mice entered and left the center of 
the open field.  All dependent variables for the open field tests were reported as means 
(+/- SEM).   
As noted earlier, the subjects in all groups were treated with saline before and 
after drug treatment.  This allowed for a determination whether there was an increase or 
decrease in FPS or startle magnitude after weeks of drug testing.  The FPS for saline 
before versus after drug testing were compared using a paired-samples t-test.  A paired-




noise-only trials to see if potentiation did occur as a result of activating the light stimulus.  
A two-factor mixed measures ANOVA was used, with sex as the between-subjects factor 
and drug dose as the within-subjects factor for each group, to determine if there was a sex 
difference and/or an interaction between sex and drug dose for FPS.  Because it was also 
of interest to determine the effects of each drug dose within each sex alone on FPS and 
startle magnitude, a one-way repeated measure ANOVA was used to analyze the effects 
of each dose on FPS and startle magnitude within each group of male or female subjects.  
Any statistically significant differences were further analyzed using Bonferroni post hoc 
tests.   
Total distance traveled in the open field was analyzed using a one-way repeated 
measure ANOVA for each group to assess if locomotor activity was also affected.  Total 
time spent in the center was assessed using a one-way repeated measure ANOVA for 
each group.  Total entries and exits from the center were analyzed using a one-way 
repeated measure ANOVA.  All statistical analyses were conducted using GraphPad 








 There was no statistical difference in FPS between saline before (M=12.30, 
SEM=3.79) and after (M=17.65, SEM=3.73) testing PD149163 in male mice, t(14)=0.99, 
p=0.34 (data not shown).  There was no statistical difference in percent FPS between 
saline before (M=16.81, SEM=4.07) and after (M=12.67, SEM=4.35) testing PD149163 
in female mice, t(14)=0.66, p=0.52 (data not shown). 
The light-noise startle magnitude was compared to the noise only startle 
magnitude for saline (i.e., the mean of saline values before and after testing PD149163) 
in the male PD149163 group.  There was a statistically significant increase in the startle 
magnitude in the light-noise (M=965.7, SEM=61.72) condition compared to the noise-
only (M=803.8, SEM=49.32) condition for males, t(29)=5.83, p<0.0001 (Figure 2 top).  
The light-noise and noise-only startle magnitude was also compared for saline in the 
female PD149163 group.  There was also a statistically significant increase in startle 
magnitude in the light-noise (M=736.7, SEM=36.94) condition compared to the noise-
only (M=613.1, SEM=27.12) condition for female; t(29)=5.115, p<0.0001 (Figure 2 
bottom).  
A two-way mixed factor ANOVA for FPS between sex and dose of PD149163 
revealed a statistically significant effect of dose, F(3,84)=6.84, p=0.0004, and sex, 
F(1,28)=13.79, p=0.0009, but no interaction, F(3,84)=2.18, p=0.10 (Figure 3).  




significantly decreased when compared to males.  Figure 4 (top) shows the FPS for saline 
or PD149163 administration to male mice.  PD149163 administration significantly 
altered the FPS, F(2.35, 32.86)=3.56, p=0.034, in male mice.  This was due to a 
significant increase in FPS at the 0.1 (mg/kg) dose when compared to saline.  Figure 4 
(bottom) shows the FPS for saline or PD149163 administration to female mice.  
PD149163 administration significantly altered the FPS, F(2,27.90)=5.22, p=0.01, in 
female mice.  This was due to a significant decrease in FPS at the 1.0 (mg/kg) dose when 
compared to saline. 
A two-way mixed factor ANOVA for startle magnitude between sex and light-
noise trials revealed a significant effect for dose, F(3,84)= 112.0, p<0.0001, sex, F(1,28)= 
8.56, p=0.0067, and interaction, F(3,84)= 4.16, p=0.0085 (data not shown).  Further 
analysis showed saline an 0.1 mg/kg to be significantly decreased in females compared to 
males. A two-way mixed factor ANOVA for startle magnitude between sex and noise-
only trials revealed a significant effect for dose, F(3,84)= 95.28, p<0.0001, sex, F(1,28)= 
4.237, p=0.049, and interaction, F(3,84)= 4.14, p=0.0087 (data not shown).  Further 
analysis showed saline to be significantly decreased in females compared to males.   A 
one-way repeated measures ANOVA for startle magnitude during the light-noise trials 
for male mice was significantly different across doses of PD149163; F(2.28, 
31.92)=49.15, p<0.0001 (Figure 5 top).  This was due to a significant decrease in startle 
magnitude at the 0.3 and 1.0 (mg/kg) doses compared to saline.  Startle magnitude during 
the noise-only trials for male mice was also significantly different across doses of 
PD149163; F(2.07, 29.00)=46.12, p<0.0001 (Figure 5 bottom).  This was due to a 




saline.  Startle magnitude during the light-noise trials for female mice was significantly 
different across doses of PD149163; F(2.54, 35.54)=93.50, p=0.0015 (Figure 6 top).  This 
was due to a significant decrease in mean startle magnitude at the 0.1, 0.3, and 1.0 mg/kg 
doses compared to saline.  Startle magnitude during the noise-only trials for female mice 
was significantly different across doses of PD149163; F(2.57, 35.97)=60.64, p=0.0027 
(Figure 6 bottom).  This was due to a significant decrease in startle magnitude at the 0.1, 
0.3, and 1.0 mg/kg doses compared to saline.   
 A two-way mixed factor ANOVA for total distance traveled (cm) between sex 
and dose of PD149163 revealed a statistically significant effect of dose, F(5,140)=181.8, 
p<0.0001, but neither sex [F(1,28)=0.26, p=0.62] nor the interaction, F(5,140)=1.40, 
p=0.23.  Figure 7 (top) shows the total distance traveled (cm) after saline or PD149163 
administration to male mice.  PD149163 administration significantly altered the total 
distance traveled in male mice, F(2.33, 32.60)=150.0, p<0.0001.  There was a significant 
decrease in total distance traveled at doses of 0.1, 0.3, and 1.0 mg/kg when compared to 
saline in male mice.  Figure 7 (bottom) shows the total distance traveled (cm) after saline 
or PD149163 administration to female mice.  PD149163 administration significantly 
altered the total distance traveled in female mice, F(3.17, 44.35)=61.99, p=0.0007.  There 
was a significant decrease in total distance traveled at doses of 0.1, 0.3, and 1.0 mg/kg 
when compared to saline in female mice. 
 A two-way mixed factor ANOVA for total time (s) spent in center between sex 
and dose of PD149163 revealed a statistically significant effect of dose, F(5,140)=16.92, 
p<0.0001, and interaction, F(5,140)=4.26, p=0.0012, but not sex, F(1, 28)=3.80, p=0.06.  




mice when compared to male mice at the doses of 0.3 and 1.0 mg/kg.  Figure 8 (top) 
shows the total time spent in center (sec) after saline or PD149163 administration to male 
mice.  PD149163 administration did significantly alter the total time spent in center in 
male mice, F(1.88, 26.41)=15.89, p=0.0018.  This is due to an increase in total time spent 
in the center at a dose of 1.0 mg/kg compared to saline in male mice. The total number of 
entries and exits of the center area was significantly altered in male mice, F(2.49, 
34.79)=21.74, p<0.0001 (Figure 9 top).  This was due to a significant decrease at the 0.3 
and 1.0 mg/kg doses.  Figure 8 (bottom) shows the total time spent in center (sec) after 
saline or PD149163 administration to female mice.  PD149163 administration 
significantly altered the time spent in center in female mice, F(1.93, 26.97)=5.95, 
p=0.0078. This is due to an decrease in total time spent in the center at a dose of 0.3 
mg/kg in female mice.  The total number of entries and exits of the center area was 
significantly altered in female mice, F(2.58, 36.15)=15.74, p<0.0001 (Figure 9 bottom).  






PD149163 Startle Magnitude: Saline 
 
 
Figure 2: The light-noise and noise-only startle magnitude during saline administration 
for the PD149163 group in male (top) and female (bottom) mice.  ****p<0.0001 





Effects of PD149163 on FPS 
 
Figure 3: The effect of PD149163 administration on FPS in male (square) and female 




Effects of PD149163 on FPS 
  
 
Figure 4: The effect of PD149163 administration on FPS in male (top) and female 






PD149163 Startle Magnitude: Male Light-Noise and Noise-only 
 
 
Figure 5: The light-noise (top) and noise only (bottom) startle magnitude during 
PD149163 administration compared to saline in male mice.  *p<0.05 & ****p<0.0001 












Figure 6: The light-noise (top) and noise only (bottom) startle magnitude during 
PD149163 administration compared to saline in female mice.  *p<0.05 & ****p<0.0001 








PD149163: Distance Traveled 
 
 
Figure 7: The effects of PD149163 on total distance traveled (cm) in the open field 
apparatus in male (top) and female (bottom) mice.  *p<0.05 & ****p<0.0001 versus 





PD149163: Time Spent in the Center 
 
 
Figure 8: The effects of PD149163 on the total time (s) spent in the center of the open 
field apparatus compared to saline in male (top) and female (bottom) mice.  *p<0.05 & 








Figure 9: The effects of PD149163 on the total exits and entries of the center of the open 
field apparatus compared to saline in male (top) and female (bottom) mice.  **p<0.01, 
***p<0.001 & ****p<0.0001 versus saline. Data are expressed as mean +/- SEM, N=15.  





There was not a statistical difference in FPS between saline before (M=13.28, 
SEM=2.67) and after (M=19.42, SEM=3.68) testing β-Lactotensin in male mice, 
t(14)=1.61, p=0.13 (data not shown). There was not a statistical difference in FPS 
between saline before (M=6.78, SEM=5.11) and after (M=16.62, SEM=3.14) testing β-
Lactotensin in female mice, t(14)=1.65, p=0.12 (data not shown).    
The light-noise startle magnitude was compared to the noise-only startle 
magnitude for saline (i.e., the mean of saline values before and after testing β-
Lactotensin) in the male β-Lactotensin group.  There was a statistically significant 
increase in the startle magnitude in the light-noise (M=1064, SEM=41.39) condition 
compared to the noise-only (M=884.7, SEM=37.10) condition for males, t(29)=6.31, 
p<0.0001 (Figure 10 top).  The light-noise and noise-only startle magnitude for saline 
was compared in the female β-Lactotensin group.  There was also a statistically 
significant increase in the startle magnitude in the light-noise (M=762, SEM=43.54) 
condition compared to the noise-only (M=661.6, SEM=37.13) condition for female, 
t(29)=4.07, p=0.0003 (Figure 10 bottom). 
A two-way mixed factor ANOVA for FPS between sex and dose of β-Lactotensin 
revealed a statistically significant effect of sex, F(1,28)=8.09, p=0.008, interaction, 
F(3,84)=2.74, p=0.049, but not dose, F(3,84)=2.033, p=0.11 (Figure 11).  A Bonferroni 
post hoc test confirmed that the dose of 0.3 mg/kg for females significantly decreased 
compared to males.  Figure 12 (top) shows the FPS for saline or β-Lactotensin 
administration to male mice.  β-Lactotensin administration did not statistically 




(bottom) shows the FPS for saline or β-Lactotensin administration to female mice.  β-
Lactotensin administration significantly altered the FPS in female mice, 
F(2.27,31.75)=3.75, p=0.03.  The post hoc analysis did not identify doses that differed 
statistically from saline.     
A two-way mixed factor ANOVA for startle magnitude between sex and light-
noise trials revealed a significant effect for dose, F(3,84)= 3.401, p=0.0214, sex, F(1,28)= 
20.39, p=0.0001, but no interaction, F(3,84)= 1.675, p=0.1786 (data not shown).  Further 
analysis showed saline, 0.1, 0.3, and 1.0 mg/kg to be significantly decreased in females 
compared to males.  A two-way mixed factor ANOVA for startle magnitude between sex 
and noise-only trials revealed a significant effect for sex, F(1,28)= 14.83, p=0.0006, but 
not for dose, F(3,84)= 2.239, p=0.0897, nor interaction, F(3,84)= 0.7623, p=0.5184 (data 
not shown).  Further analysis showed saline, 0.1 and 0.3 mg/kg to be significantly 
decreased in females compared to males.  A one-way repeated measure ANOVA for 
startle magnitude during the light-noise trials for β-Lactotensin was not significantly 
different in male mice across doses; F(2.23, 31.14)=1.05, p=0.37 (Figure 13 top).  Startle 
magnitude during the noise-only trials for β-Lactotensin was not significantly different in 
male mice across doses; F(2.64, 36.96)=1.53, p=0.23 (Figure 13 bottom).  Startle 
magnitude during the light-noise trials for β-Lactotensin was significantly different in 
female mice across doses; F(2.92, 40.90)=5.64, p=0.0027 (Figure 14 top).  This was due 
to a significant decrease in startle magnitude at the 0.3 mg/kg dose compared to saline.  
Startle magnitude during the noise-only trials for β-Lactotensin was significantly 




This was due to a significant decrease in startle magnitude at the 0.1 mg/kg dose 
compared to saline.     
A two-way mixed factor ANOVA for total distance traveled (cm) between sex 
and dose of β-Lactotensin revealed a statistically significant effect of dose, 
F(5,140)=11.62, p<0.0001, but neither sex, F(1, 28)=0.004, p=0.95, nor the interaction, 
F(5,140)=0.28, p=0.92.  Figure 15 (top) shows the total distance traveled (cm) after saline 
or β-Lactotensin administration to male mice.  β-Lactotensin administration significantly 
altered the total distance traveled in male mice, F(3.22, 45.02)=7.92, p=0.0002.  A 
significant decrease of total distance traveled was shown at doses of 0.1, 0.3 and 1.0 
mg/kg compared to saline in male mice.  Figure 15 (bottom) shows the total distance 
traveled (cm) after saline or β-Lactotensin administration to female mice.  β-Lactotensin 
administration significantly altered the total distance traveled in female mice, F(2.78, 
38.93)=4.75, p=0.0076.  The post hoc analysis did not identify doses that differed 
statistically from saline.    
 A two-way mixed factor ANOVA for total time (sec) spent in center between sex 
and dose of β-Lactotensin revealed no statistically significant effect of dose, 
F(5,140)=2.02, p=0.08, sex, F(1,28)=1.10, p=0.30, and interaction, F(5,140)=1.27, 
p=0.28.  Figure 16 (top) shows the total time spent in center (sec) after saline or β-
Lactotensin administration to male mice.  β-Lactotensin administration did not 
significantly altered the total time spent in center in male mice, F(3.20, 44.75)=2.17, 
p=0.10.  The total number of entries and exits of the center area was not significantly 
altered in male mice, F(2.70, 37.75)=0.61, p=0.60 (Figure 17 top).  Figure 16 (bottom) 




female mice.  β-Lactotensin administration did not significantly altered the time spent in 
center in female mice, F(2.97, 41.64)=1.26, p=0.29. The total number of entries and exits 
of the center area was not significantly altered in female mice, F(2.15, 30.12)=1.64, 






β-Lactotensin Startle Magnitude: Saline 
 
  
Figure 10: The light-noise and noise-only startle magnitude during saline administration 
for the β-Lactotensin group in male (top) and female (bottom) mice.  ***p<0.001 & 





The Effects of β-Lactotensin on FPS 
 
 
Figure 11: The effect of β-Lactotensin administration on FPS in male (square) and female 









Figure 12: The effect of β-Lactotensin administration on percent fear-potentiated startle 













Figure 13: The light-noise (top) and noise only (bottom) startle magnitude during β-
Lactotensin administration compared to saline in male mice.  Data are expressed as mean 



















Figure 14: The light-noise (top) and noise only (bottom) startle magnitude during β-
Lactotensin administration compared to saline in female mice.  *p<0.05 & **p<0.01 
















Figure 15: The effects of β-lactotensin on the total distance traveled (cm) in the open 
field apparatus in male (top) and female (bottom) mice.  *p<0.05 & **<0.01 versus 











Figure 16: The effects of β-Lactotensin on the total time (s) spent in the center of the 
open field apparatus compared to saline in male (top) and female (bottom) mice.  *p<0.05 










Figure 17: The effects of β-Lactotensin on the total exits and entries of the center of the 
open field apparatus compared to saline in male (top) and female (bottom) mice.  Data 
are expressed as mean +/- SEM, N=15.  
β-Lactotensin (mg/kg) 
β-Lactotensin (mg/kg) 






 There was no statistical difference in FPS between saline before (M=19.10, 
SEM=2.43) and after (M=21.88, SEM=4.15) testing buspirone in male mice, t(14)=0.50, 
p=0.63.  There was no statistical difference in FPS between saline before (M=21.18, 
SEM=4.12) and after (M=21.7, SEM=4.23) testing buspirone in female mice, t(14)=0.02, 
p=0.98.   
 The light-noise startle magnitude was compared to the noise-only startle 
magnitude for saline (i.e., the mean of saline values before and after testing buspirone) in 
the male buspirone group.  There was a statistically significant increase in the startle 
magnitude in the light-noise (M=1067, SEM=61.24) condition compared to the noise-
only (M=852.6, SEM=52.36) condition for males, t(29)=8.41, p<0.0001 (Figure 18 top).  
The light-noise and noise-only startle magnitude for saline was also compared in the 
female buspirone group.  There was also a statistically significant increase in the startle 
magnitude in the light-noise (M=718.6, SEM=41.82) condition compared to the noise 
only (M=553.7, SEM=30.02) condition for female, t(29)=7.02, p<0.0001 (Figure 18 
bottom).   
A two-way mixed factor ANOVA for FPS between sex and dose of buspirone 
revealed no statistically significant effect of dose, F(3,84)=0.71, p=0.55, sex, 
F(1,28)=0.15, p=0.70, and interaction, F(3,84)=0.41, p=0.74 (Figure 19).  Figure 20 (top) 
shows the FPS for saline or buspirone administration to male mice.  Buspirone 




p=0.26.  Figure 20 (bottom) shows the FPS for saline or buspirone administration to 
female mice.  Buspirone administration did not significantly altered the FPS, 
F(2.75,38.51)=0.14, p=0.92, in female mice.    
A two-way mixed factor ANOVA for startle magnitude between sex and light-
noise trials revealed a significant effect for dose, F(3,84)= 10.12, p<0.0001, sex, F(1,28)= 
18.65, p=0.0002, but no interaction, F(3,84)= 1.139, p=0.3382 (data not shown).  Further 
analysis showed saline, 1.0, 2.5 and 5.0 mg/kg to be significantly decreased in females 
compared to males.  A two-way mixed factor ANOVA for startle magnitude between sex 
and noise-only trials revealed a significant effect for dose, F(3,84)= 7.538 , p=0.0002, 
sex, F(1,28)= 15.74, p=0.0003, but no interaction, F(3,84)= 0.4127, p=0.7443 (data not 
shown).  Further analysis showed saline, 1.0, 2.5 and 5.0 mg/kg to be significantly 
decreased in females compared to males.  A one-way repeated measure ANOVA for 
startle magnitude during the light-noise trials for buspirone was significantly different in 
male mice across doses, F(2.28, 31.86)=3.62, p=0.03 (Figure 21 top).  This was due to a 
significant decrease in startle magnitude at the dose of 5.0 mg/kg compared to saline.  
Startle magnitude during the noise-only trials for buspirone was not significantly 
different in male mice across doses; F(2.79, 39.01)=1.71, p=0.18 (Figure 21 bottom).  
Startle magnitude during the light-noise trials for buspirone was significantly different in 
female mice across doses; F(2.43, 34.06)=9.32, p=0.0003 (Figure 22 top).  This was due 
to a significant decrease in startle magnitude at the 2.5 and 5.0 mg/kg doses compared to 
saline.  Startle magnitude during the noise-only trials for buspirone was significantly 




bottom).  This was due to a significant decrease in startle magnitude at the 1.0, 2.5 and 
5.0 mg/kg doses compared to saline.     
 A two-way mixed factor ANOVA for total distance traveled (cm) between sex 
and dose of buspirone revealed a statistically significant effect of dose, F(5,140)=43.75, 
p<0.0001, but neither sex, F(1,28)=0.06, p=0.81, nor the interaction, F(5,140)=0.89, 
p=0.49.  Figure 23 (top) shows the total distance traveled (cm) after saline or buspirone 
administration to male mice.  Buspirone administration significantly altered the total 
distance traveled in male mice, F(3.19, 44.59)=27.77, p<0.0001.  This was due to a 
significant decrease in total distance traveled at the 1.0, 2.5 and 5.0 mg/kg doses in male 
mice.  Figure 23 (bottom) shows the total distance traveled (cm) after saline or buspirone 
administration to female mice.  Buspirone administration significantly altered the total 
distance traveled in female mice, F(2.77, 38.83)=17.49, p<0.0001.  This was due to a 
significant decrease in total distance traveled at the 1.0, 2.5, and 5.0 mg/kg doses in 
female mice.   
 A two-way mixed factor ANOVA for total time (sec) spent in center between sex 
and dose of buspirone revealed a statistically significant effect of dose, F(5,140)=7.94, 
p<0.0001, but neithor sex, F(1,28)=1.07, p=0.31, not the interaction, F(5,140)=0.89, 
p=0.49.  Figure 24 (top) shows the total time spent in center (sec) after saline or 
buspirone administration to male mice.  Buspirone administration significantly altered the 
total time spent in center, F(3.14, 43.90)=8.92, p<0.0001, in male mice.  This is due a 
significant increase in time spent in the center for the 1.0, 2.5, and 5.0 mg/kg doses in 
male mice.  The total number of entries and exits of the center was significantly altered in 




significant decrease at the 1.0, 2.5 and 5.0 mg/kg doses.  Figure 24 (bottom) shows the 
total time spent in center (sec) after saline or buspirone administration to female mice.  
Buspirone administration did not significantly altered the time spent in center, F(2.94, 
41.17)=2.15, p=0.11, in female mice.  The total number of entries and exits of the center 
was significantly altered in female mice, F(2.54, 35.54)=5.84, p=0.0037 (Figure 25 









Figure 18: The light-noise and noise-only startle magnitude during saline administration 
for the buspirone group in male (top) and female (bottom) mice.  ****p<0.0001 









The Effects of buspirone on FPS 
 
Figure 16: The effect of buspirone administration on FPS in male (square) and female 






   
Figure 17: The effect of buspirone administration on percent fear-potentiated startle in 
male (top) and female (bottom) mice.  Data are expressed as mean +/- SEM, N=15.    
  






Figure 18: The light-noise (top) and noise only (bottom) startle magnitude during 
buspirone administration compared to saline in male mice.  *p<0.05 versus saline.  Data 
are expressed as mean +/- SEM, N=15. 
 








Figure 19: The light-noise (top) and noise only (bottom) startle magnitude during β-
Lactotensin administration compared to saline in female mice.  *p<0.05, **p<0.01 & 
****p<0.0001 versus saline.  Data are expressed as mean +/- SEM, N=15. 
  









Figure 20: The effects of buspirone on the total distance traveled in male (top) and female 
(bottom) mice.  **p<0.01, ***p<0.001 & ****p<0.0001 versus saline.  Data are 
expressed as mean +/- SEM, N=15.   
  






Figure 21: The effects of buspirone on the total time (s) spent in the center of the open 
field apparatus in male (top) and female (bottom) mice.  *p<0.05 & **p<0.01 versus 
saline.  Data are expressed as mean +/- SEM, N=15. 
  






Figure 22: The effects of buspirone on the total exits and entries of the center of the open 
field apparatus compared to saline in male (top) and female (bottom) mice.  *p<0.05, 
**p<0.01 & ***p<0.001 versus saline.  Data are expressed as mean +/- SEM, N=15. 
  






This was the first study to examine PD149163 and β-Lactotensin in male and 
female mice using a fear-potentiated startle paradigm.  The present study demonstrated 
the differential effects of PD149163, a NTS1 agonist, β-Lactotensin, a NTS2 agonist, and 
buspirone, an anxiolytic and partial 5-HT1A agonist, on FPS, startle magnitude, in male 
and female mice.  PD149163 did not decrease, but rather increased FPS in male mice.  
Female mice, however, showed a decrease in FPS at the highest dose of PD149163.  β-
Lactotensin, at the doses tested, did not statistically increase or decrease FPS, however 
there was a significant decrease in female mice at the 0.3 mg/kg dose compared to male 
mice.  Finally, there were no significant differences found in percent FPS using 
buspirone.   
We examined the effect of multiple treatments in male and female mice, by 
testing saline before and after drug treatment and found no significant decrease in FPS for 
any group.  This indicates that habituation did not occur over time, and suggests that any 
decreases in FPS occurred due to treatment.  This may have been due to the training 
session 24 hours prior to each test session and gives support for a repeated measures 
design in order to study FPS. Winslow et al. (2007) also used a within subjects to study 
FPS in monkeys.  Rhesus monkeys developed a persistent increase of the startle response 
when the CS was on during test sessions.  A training session was completed prior to each 




 A significant increase in FPS in the PD14963 male group was found at the 0.1 
mg/kg dose.  We further examine this effect and looked at the differences between the 
light-noise and noise-only startle magnitude.  When comparing the different trials, the 
light-noise trials decreased in startle magnitude but not enough to be considered different 
from saline and the noise-only trials decreased enough to be considered different from 
saline.  This may indicate that PD149163 did not have an effect (or as strong of an effect) 
on the cue light, but decreased the sensitivity of the subject more during the noise only 
trials. The increase in FPS is contradictory to previous research.  Shilling & Feifel (2008) 
found a decrease in FPS following administration of PD149163 in rats.  Although 
PD149163 has been shown to decrease total distance traveled in mice, the decrease in 
locomotor activity was not thought to be a factor for the increase in FPS in male mice 
(Vadnie et al., 2014).  In fact, one would hypothesize to see a decrease in FPS if 
locomotor activity also decreased.  Time spent in the center and entries and exits of the 
center was not affected, therefore the subject was not trying to avoid the center which 
would be an indicator of an anxiolytic effect.  Given the decrease in locomotor data, and 
no effect on time spent in the center and total entries and exits of the center, one would 
predict a decrease in FPS, however the opposite was found.    
 Females expressed a decrease in FPS after a dose of 1.0 mg/kg of PD149163.  
Both the light-noise and noise-only startle magnitude were decreased.  The startle 
magnitudes were similar to that of a dummy weight in the chamber, meaning that the 
animals were not startling as much when the noise was produced regardless of the light 




decreased at the high dose.  A possible reason for why the females showed a decrease in 
the FPS was due to a decrease in locomotor activity.   
NTS1 receptor knockout male mice traveled less and spent less time in the center 
of an open field compared to wild-type controls (Fitzpatick et al., 2012).  While the male 
mice FPS data are contradictory to previous research, the female mice showed similar 
effects found by administration of PD149163.  A decrease in FPS and startle magnitude 
following administration of PD149163 was previously found in rats (Shilling & Feifel, 
2008).  Vadnie et al. (2014) found a decrease in locomotor activity following injections 
of PD149163 in mice.  Our study further supports that PD149163, at higher doses, 
disrupts general behavior. 
β-Lactotensin decreased females FPS when compared to males at the 0.3 mg/kg 
dose.  We further examined this effect by looking at the startle magnitudes for light-noise 
and noise-only trials.  The light-noise startle magnitude was significantly decreased after 
administration of the 0.3 mg/kg dose of β-Lactotensin, while the noise-only startle 
magnitude was not affected.  The locomotor activity, time spent in the center, and 
number of entries and exits of the center did not increase or decrease, therefore locomotor 
inhibition alone cannot explain the decrease in FPS at the 0.3 mg/kg dose.  Baseline 
acoustic startle was not different between NTS1 and NTS2 knockout and wild-type mice, 
and showed that different drugs affected pre-pulse inhibition differently in NTS1 and 
NTS2 knockout mice (Oliveros et al., 2010).  This lends support to continue studying the 




Previous research indicated that buspirone blocked FPS in rats (Kehne, Cassella, 
and Davis, 1988; Risbrough et al., 2003).  Our study found buspirone did not affect FPS 
in either male or female mice.  This could be due to the way the subjects were trained.  
Moderate shocks produced enhanced startle amplitudes, while higher intensity shocks 
produced lower startle amplitudes (Walker et al., 1997).  In rats, 0.4 mA produced the 
biggest difference between light-noise and noise-only conditions with a decrease in 
startle amplitude and FPS at higher intensities.  Our study used 0.3 mA and pilot data 
showed an increase of a 30-40 percent FPS (unpublished).   
Male and female rat NT mRNA expression and NT immunoreactivity is similar 
until the fifth week of postnatal life.  This is when the sexual dimorphism of NT 
expression is established due to the presence sex hormone levels (Bello et al., 2004).  NT 
mRNA expression and NT immunoreactivity in female rats are different than males, and 
the levels fluctuate during the estrous cycle (Kinkead et al., 2000). Further, estrogen has 
been shown to enhance NT/neuromedin gene expression (Watters & Dorsa, 1998).  NT 
immunoreactive levels oscillate during the estrous cycle and are high during diestrus and 
low during estrous (Bello et al., 1999).  Hiroi and Neumaier (2005) showed that 
injections of estrogen in ovariectomized female rats increased fear potentiated startle 
when compared to ovariectomized females without injections of estrogen.  Perhaps the 
estrous cycle had an interaction with the drugs.  Future research may want to control the 
estrous cycle by using ovariectomized female mice.    
 NTS1 expression has been found in a variety of human tumors; Ewing’s sarcoma, 
meningioma, astrocytoma, medullablastoma, and medullary thyroid cancers had the 




NTS1 agonists may simulate tumor growth in lung, pancreatic, colon, prostate, and breast 
cancer, and NTS1 antagonists may inhibit tumor growth in these cancers (For review see: 
Carraway & Plona, 2006).  Further support shows that SR48692, a neurotensin receptor 
antagonist, inhibits the growth of small cell lung cancer cells (Moody, Chiles, Casibang, 
Moody, Chan, and Davis, 2001).  While NTS1 is associated with progressing tumor and 
cancer growth, the NTS2 receptor has not been implicated in cancer progression (Leyton, 
Garcia-Marin, Jensen, and Moody, 2002).  With the decrease at the 0.3 mg/kg dose of β-
Lactotensin, further research may want to examine the effects of a more selective NTS2 
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FPS1 Male 12/30/15 1/5/16 1/12/16 1/19/16 1/26/16 
FPS2 Male  12/30/15 1/5/16 1/12/16 1/19/16 1/26/16 
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FPS75 Female 2/23/16 3/6/16 3/12/16 2/29/16 3/19/16 











Project Title (If using external funds, enter the title used on the grant application): The 
Effects of Neurotensin on the Expression of Fear-Potentiated Startle in Mice 
General Instructions Shaded area for IACUC use only. 
 
Please check the  IACUC website to ensure   
 
you are using the current version of the form. Application Number: 254 Amended 
 
All parts of this form must be submitted Date Application Received: November 2, 2015 
 
electronically to the Institutional Animal Care ☒Approved ☐ Denied on November 9, 2015  
and Use Committee (email:    
 





Department Head or other departmental designee. Review of this application will 
commence upon receiving the electronic application, but the project may not begin 
until all required approval signatures are obtained via Right Signature. Please contact 
the IACUC chair (email:  IACUCChr@nmu.edu) if you have any questions. 
Review Dates:  
Designated Member Review of applications (appropriate for USDA Use Categories B and 
C) will be completed within two weeks after receipt of the electronic application. 
Full Committee Review of applications will take place on the last Friday of every month. 
Applications for Full Committee Review must be electronically received by the first Friday of 
the month. Full Committee Review is required for applications that fall under USDA Use 
Categories D and E. Applications that fall under USDA Use Categories B and C will receive 
Full Committee Review if requested by an IACUC member. Detailed procedures on the 
IACUC review processes are located at the  IACUC website. 
I. Principal Investigator (Must be a faculty member or Department Head): Adam Prus 
Co- Investigator: Mark Vanden Avond 
Department: Psychology 
Phone number: x2941 
II.  Funding Sources/Course Information and Dates 
If the proposed work is for a course, please include the number of the course and 
title of the course 
 
Assessment of fear potentiated startle in mice 
 
Funding Sources (External & Internal, if applicable) Internal? 
 
Additional Funding Pending (click on the correct box)? ☒Yes          ☐No 
 
Project/Course Start Date:  January 5, 2015  
End Date (three year maximum): 1/5/2017 
 
This application is (check one) ☒New ☒ Modification of an application 
currently approved by the  
Institutional Animal Care and Use Committee (a new protocol must be submitted after 
three years) 
Appendix B 
